Literature DB >> 23226624

Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Ann-Kathrin Eisfeld1, Rainer Krahl, Nadja Jaekel, Dietger Niederwieser, Haifa Kathrin Al-Ali.   

Abstract

UNLABELLED: Excess body iron could persist for years after allogeneic hematopoietic cell transplantation (HCT) with possible deleterious sequels. An iron depletive therapy with phlebotomy seems rational. Kinetics of iron removal by phlebotomy without erythropoietin support in non-thalassemic adult patients with iron overload after HCT and the impact of pre- and post-HCT hemochromatosis (HFE) genotype on iron mobilization were investigated. PATIENTS AND METHODS: Phlebotomy was initiated in 61 recipients of allografts due to hematologic malignancies (median age 48 years) after a median of 18 months. The prephlebotomy median serum ferritin (SF) was 1697ng/ml and the median number of blood transfusions 28 units. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST), alkaline phosphates (AP), and bilirubin were elevated in 55.7%, 64% and 11.5% patients respectively. HFE-genotype was elucidated by polymerase chain reaction using hybridization probes and melting curve analysis.
RESULTS: Phlebotomy was well-tolerated irrespective of age or conditioning. A negative iron balance in 80% of patients (median SF 1086 ng/ml) and a rise in hemoglobin were observed (p<0.0001). Higher transfusional burden and SF were associated with a greater iron mobilization per session (p=0.02). In 58% of patients, a plateau after an initial steady decline in SF was followed by a second decline under further phlebotomy. The improvement in ALT (p=0.002), AST (p=0.03), AP (p=0.01), and bilirubin (p<0.0001) did not correlate with the decline in SF. Mutant HFE-gene variants were detected in 14/55 (25%) pre-HCT and 22/55 (40%) patients post-HCT. Overall, dissimilar pre- and posttransplantational HFE-genotypes were detected in 20/55 (40%) patients. Posttransplantational mutant HFE variants correlated with a slower decline in SF (p=0.007).
CONCLUSIONS: Phlebotomy is a convenient therapy of iron overload in survivors of HCT. A negative iron balance and a rise in hemoglobin were observed in the majority of patients. Liver dysfunction improved irrespective of SF reduction suggesting a probable rapid decline of the deleterious labile plasma iron. In recipients of grafts with mutant HFE variants a "mixed chimerism" of HFE in body tissues might be created with a change in the set point for iron regulation. The transient plateau in SF after an initial decline might reflect iron mobilization from various tissues.

Entities:  

Keywords:  Iron overload; allogeneic HCT; ferritin; phlebotomy

Year:  2012        PMID: 23226624      PMCID: PMC3512175     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  42 in total

Review 1.  Mutation detection using fluorescent hybridization probes and melting curve analysis.

Authors:  E Lyon
Journal:  Expert Rev Mol Diagn       Date:  2001-05       Impact factor: 5.225

2.  Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Rammurti T Kamble; George B Selby; Martha Mims; Mohamed A Kharfan-Dabaja; Howard Ozer; James N George
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

Review 3.  HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology.

Authors:  E H Hanson; G Imperatore; W Burke
Journal:  Am J Epidemiol       Date:  2001-08-01       Impact factor: 4.897

4.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation.

Authors:  Pietro Muretto; Emanuele Angelucci; Guido Lucarelli
Journal:  Ann Intern Med       Date:  2002-05-07       Impact factor: 25.391

6.  A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload.

Authors:  C Pigeon; G Ilyin; B Courselaud; P Leroyer; B Turlin; P Brissot; O Loréal
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

Review 7.  Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

8.  Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?

Authors:  A Cortelezzi; C Cattaneo; S Cristiani; L Duca; B Sarina; G L Deliliers; G Fiorelli; M D Cappellini
Journal:  Hematol J       Date:  2000

9.  Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients.

Authors:  J F Tomás; I Pinilla; M L García-Buey; A García; A Figuera; R Moreno; J M Fernández-Rañada
Journal:  Bone Marrow Transplant       Date:  2000-09       Impact factor: 5.483

10.  Effect of hepatic iron concentration reduction on hepatic fibrosis and damage in rats with cholestatic liver disease.

Authors:  Gil Peretz; Gabriela Link; Orit Pappo; Rafael Bruck; Zvi Ackerman
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

View more
  2 in total

1.  Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Authors:  A Sirvent; P Auquier; C Oudin; Y Bertrand; S Bohrer; P Chastagner; M Poirée; J Kanold; S Thouvenin; Y Perel; D Plantaz; M-D Tabone; K Yakouben; V Gandemer; P Lutz; N Sirvent; C Vercasson; J Berbis; H Chambost; G Leverger; A Baruchel; G Michel
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

2.  Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.

Authors:  N Jaekel; K Lieder; S Albrecht; O Leismann; K Hubert; G Bug; N Kröger; U Platzbecker; M Stadler; K de Haas; S Altamura; M U Muckenthaler; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.